Your browser is no longer supported. Please, upgrade your browser.
Settings
GALE Galena Biopharma, Inc. daily Stock Chart
GALE [NASD]
Galena Biopharma, Inc.
Index- P/E- EPS (ttm)-0.24 Insider Own0.43% Shs Outstand181.59M Perf Week8.24%
Market Cap121.87M Forward P/E- EPS next Y-0.25 Insider Trans0.00% Shs Float180.98M Perf Month-15.05%
Income-36.10M PEG- EPS next Q-0.05 Inst Own14.90% Short Float10.80% Perf Quarter-61.21%
Sales3.20M P/S38.08 EPS this Y63.50% Inst Trans-0.76% Short Ratio12.52 Perf Half Y-55.26%
Book/sh0.20 P/B3.36 EPS next Y21.90% ROA-67.20% Target Price3.92 Perf Year-60.05%
Cash/sh0.19 P/C3.50 EPS next 5Y- ROE-141.10% 52W Range0.59 - 2.39 Perf YTD-54.35%
Dividend- P/FCF- EPS past 5Y24.20% ROI-114.50% 52W High-71.92% Beta1.26
Dividend %- Quick Ratio1.50 Sales past 5Y- Gross Margin71.90% 52W Low13.75% ATR0.08
Employees57 Current Ratio1.50 Sales Q/Q- Oper. Margin- RSI (14)31.33 Volatility10.06% 10.11%
OptionableYes Debt/Eq0.18 EPS Q/Q-33.30% Profit Margin- Rel Volume0.48 Prev Close0.64
ShortableYes LT Debt/Eq0.05 EarningsMar 10 AMC Payout- Avg Volume1.56M Price0.67
Recom2.00 SMA20-6.53% SMA50-42.10% SMA200-55.61% Volume748,225 Change4.86%
Dec-22-15Reiterated Maxim Group Buy $7 → $4
Dec-08-15Upgrade Cantor Fitzgerald Sell → Hold
Nov-12-15Upgrade Oppenheimer Perform → Outperform $4
Nov-10-15Reiterated ROTH Capital Buy $8 → $6
Sep-09-15Initiated Raymond James Outperform
Mar-09-15Reiterated Needham Buy $7 → $4
Nov-20-14Reiterated MLV & Co Buy $3 → $5
Aug-22-14Reiterated MLV & Co Buy $5 → $3.50
Aug-12-14Reiterated Needham Buy $9 → $7
Feb-03-14Reiterated Noble Financial Buy $4 → $6
Jan-21-14Reiterated Maxim Group Buy $9 → $11
Jan-08-14Reiterated Maxim Group Buy $6 → $9
Nov-26-13Initiated Oppenheimer Outperform $6
Mar-25-13Initiated Needham Buy $3.50
Nov-28-12Initiated Aegis Capital Buy $6
Nov-05-12Initiated Maxim Group Buy $5
Oct-25-12Initiated MLV & Co Buy $6
Jun-04-12Initiated Cantor Fitzgerald Buy $4
Feb-08-16 07:05AM  Galena Biopharma Announces Notice of Allowance of U.S. Patent for NeuVax (nelipepimut-S) GlobeNewswire
Feb-02-16 07:05AM  Galena Biopharma to Present at the BIO CEO & Investor Conference GlobeNewswire
Jan-21-16 04:10PM  Galena Biopharma Presents Observational Study Data in Gastric Cancer Patients at the ASCO 2016 Gastrointestinal Cancers Symposium GlobeNewswire
Jan-13-16 01:37PM  Galena Biopharma 2016 Outlook Focuses On 'High Value' Cancer Immunotherapy Pipeline -7.41%
07:05AM  Galena Biopharma Provides 2016 Outlook GlobeNewswire
Jan-11-16 07:05AM  Galena Biopharma to Present at NobleCon12 - Noble Financial Capital Markets Twelfth Annual Investor Conference GlobeNewswire
Jan-07-16 04:51PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement -27.91%
12:33PM  Why Are These Stocks Losing Ground Today? at Insider Monkey
09:25AM  Galena Biopharma Announces Pricing of Public Offering of Common Stock and Warrants GlobeNewswire
Jan-06-16 04:26PM  Galena Biopharma Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire -6.52%
Dec-31-15 12:31PM  Galena Biopharma Sells Zuplenz to Focus on Cancer Pipeline
Dec-30-15 07:21PM  Tax-Loss Selling: 1 Stock We'd Be Glad to Sell Right Now at Motley Fool
02:00AM  Midatech Completes Acquisition of Zuplenz® GlobeNewswire
Dec-29-15 08:57AM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisition
Dec-27-15 09:12AM  This Is the Most Effective Way to Treat Lung Cancer, Study Shows at Motley Fool
Dec-24-15 08:36AM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibi
08:05AM  Market Influences That Drive Equities Forward - New Research on Galena Biopharma, XBiotech, KEMET and Control4 Accesswire
07:05AM  Galena Biopharma Announces a Change to Its Board of Directors GlobeNewswire
Dec-23-15 07:35AM  Morning Movers: Celgene Jumps on Patent Settlement; Finish Line Gains on Upgrade at Barrons.com
Dec-22-15 04:42PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Other Events
Dec-18-15 08:35AM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhib
07:05AM  Galena Biopharma to Sell Zuplenz® (ondansetron) Oral Soluble Film, Completing Divestiture of Commercial Operations GlobeNewswire
02:00AM  Midatech Agrees to Acquire Marketed Oncology Product, Zuplenz®, From Galena Biopharma, Inc. GlobeNewswire
Dec-14-15 08:54AM  Galena Biopharma (GALE): Strong Industry, Solid Earnings Estimate Revisions
Dec-11-15 04:47PM  CFO Moves: MSA Safety, Galena Biopharma at The Wall Street Journal
07:58AM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibi
07:39AM  Galena Biopharma Gives Shareholders 3 More Reasons to Bury Their Heads in the Sand at Motley Fool
07:05AM  Galena Biopharma Announces Departure of Chief Financial Officer GlobeNewswire
Dec-08-15 01:17PM  GALENA BIOPHARMA, INC. Financials
07:05AM  Galena Biopharma Presents Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition GlobeNewswire
Dec-04-15 07:24AM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:05AM  Galena Biopharma Announces Settlement of Securities Class Action and Shareholder Derivative Lawsuits GlobeNewswire
Nov-30-15 07:05AM  Galena Biopharma to Present at the Oppenheimer 26th Annual Healthcare Conference GlobeNewswire
Nov-29-15 02:43PM  QCR Holdings, Inc. (QCRH): Are Hedge Funds Right About This Stock? at Insider Monkey
Nov-24-15 08:25AM  Market Data on Movers and Shakers - Research on HomeTrust Bancshares, Liquidity Services, Galena Biopharma and Hovnanian Enterprises Accesswire
Nov-22-15 03:52PM  Is Galena Biopharma Inc (GALE) A Good Stock To Buy? at Insider Monkey
Nov-20-15 03:03PM  3 Things Galena Biopharma Inc. Wants You to Know at Motley Fool
07:21AM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Defi
07:05AM  Galena Biopharma Completes Divestiture of Abstral(R) (fentanyl) Sublingual Tablets as Part of Strategic Focus on Its Immunotherapy Pipeline GlobeNewswire
Nov-16-15 08:25AM  Equity Price Movement at a Glance - Research on Gladstone Commercial, Liquidity Services, Galena Biopharma and Hovnanian Enterprises Accesswire
Nov-12-15 09:06AM  Galena Biopharma (GALE) Stock Rating Upgraded at Oppenheimer at TheStreet
Nov-11-15 04:42PM  Galena Biopharma's 3rd-Quarter Report Is Nothing Short of Bizarre at Motley Fool
Nov-10-15 12:56PM  Here's Why Galena Biopharma's Stock Tanked Today at Motley Fool -11.05%
12:27PM  Galena Biopharma (GALE) Stock Declines on Earnings Miss at TheStreet
12:24AM  Edited Transcript of GALE earnings conference call or presentation 9-Nov-15 10:00pm GMT
Nov-09-15 06:11PM  Galena Biopharma reports 3Q loss
05:00PM  Galena Biopharma Inc Earnings Call scheduled for 5:00 pm ET today
04:48PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, F
04:05PM  Galena Biopharma Reports Third Quarter 2015 Financial Results and Announces Exclusive Focus on Its Clinical Development Programs With Planned Divestiture of the Commercial Business GlobeNewswire
07:07AM  Q3 2015 Galena Biopharma Inc Earnings Release - After Market Close
07:05AM  Galena Biopharma Presents GALE-302 Preliminary Immunologic Data Optimizing GALE-301 at the Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting GlobeNewswire
Nov-06-15 02:26PM  4 Questions to Ask Ahead of Galena Biopharma's Third-Quarter Earnings Report at Motley Fool
09:00AM  Is a Surprise Coming for Galena Biopharma (GALE) This Earnings Season?
07:05AM  Galena Biopharma to Present Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition GlobeNewswire
Oct-30-15 09:17AM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibi
07:05AM  Galena Biopharma Appoints Bijan Nejadnik, M.D., as Executive Vice President and Chief Medical Officer GlobeNewswire
Oct-27-15 09:05AM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Other Events
Oct-26-15 07:05AM  Galena Biopharma to Report Third Quarter Financial Results and Provide Business Update on Monday, November 9, 2015 GlobeNewswire
Oct-22-15 07:05AM  Galena Biopharma to Present GALE-302 Preliminary Immunological Data Optimizing GALE-301, and the Phase 2 NeuVax(TM) Data Impact on Cancer Survivorship at Two Upcoming Medical Conferences GlobeNewswire
Oct-05-15 04:35PM  Cancer Immunotherapy Developer Galena Biopharma Can't Win for Trying at Motley Fool +7.27%
Sep-30-15 09:37PM  Galena Biopharma Just Surged 14% -- Here's Why at Motley Fool +13.67%
07:05AM  Galena Biopharma Collaborates With the National Cancer Institute on a Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) in Ductal Carcinoma in Situ Patients GlobeNewswire
Sep-28-15 07:05AM  Galena Biopharma Presents Positive GALE-301 Phase 2a Clinical Trial Data at the European Cancer Congress 2015 GlobeNewswire
Sep-23-15 12:11PM  Galena Biopharma, Inc. Earnings Q2, 2015
Sep-16-15 01:17PM  3 Small-Cap Biotech Stocks Crushing Shareholder Value With Stock Offerings at Motley Fool
Sep-14-15 07:05AM  Galena Biopharma to Present GALE-301 Phase 2a Clinical Trial Data at the European Society for Medical Oncology (ESMO) European Cancer Congress 2015 GlobeNewswire
Sep-13-15 08:24AM  3 Dangerous Biotech Stocks at Motley Fool
Sep-01-15 07:05AM  Galena Biopharma to Present at Two Upcoming Healthcare Investment Conferences GlobeNewswire
Aug-31-15 11:00AM  Galena Biopharma, Inc. Stock Alert: Schubert Firm Investigates Potential Breaches of Fiduciary Duty PR Newswire +5.33%
Aug-25-15 03:01PM  5 Things Galena Biopharma Wants You to Know at Motley Fool +7.33%
Aug-24-15 07:05AM  Galena Biopharma Announces Independent Data Safety Monitoring Committee Recommends Reduction of Cardiac Toxicity Monitoring for NeuVax(TM) PRESENT Trial GlobeNewswire +11.94%
Aug-07-15 03:32PM  Edited Transcript of GALE earnings conference call or presentation 6-Aug-15 9:00pm GMT -7.36%
10:04AM  Galena Biopharma Comes Up Short in Q2 and Investors Pounce at Motley Fool
Aug-06-15 05:00PM  Galena Biopharma Inc Earnings Call scheduled for 5:00 pm ET today
04:52PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, F
04:10PM  Galena Biopharma Reports Second Quarter 2015 Financial Results GlobeNewswire
07:07AM  Q2 2015 Galena Biopharma Inc Earnings Release - After Market Close
Aug-05-15 10:03AM  MonoSol Rx Partner Galena Biopharma Launches Zuplenz(R) (Ondanestron) Oral Soluble Film GlobeNewswire
Jul-29-15 07:05AM  Galena Biopharma Launches Zuplenz(R) (ondansetron) Oral Soluble Film GlobeNewswire +5.59%
Jul-28-15 07:05AM  Galena Biopharma to Report Second Quarter Financial Results on Thursday, August 6, 2015 GlobeNewswire +6.62%
Jun-30-15 12:02PM  Small Cap Stocks to Watch in Biotech at Motley Fool
Jun-29-15 09:47PM  Why 78% Is Galena Biopharma's Magic Number at Investopedia -5.68%
Jun-24-15 05:11PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events
Jun-15-15 07:05AM  Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Phase 2 Data at the European Hematology Association 20th Congress GlobeNewswire +5.29%
Jun-10-15 09:14PM  What's Behind Galena's 58% Rise in 2 Weeks? at Investopedia
Jun-08-15 01:38PM  3 Big Stocks on Traders' Radars -- and What to Do With Them at TheStreet
Jun-05-15 09:32AM  Galena Biopharma, Inc. (GALE) Rises: Stock Moves 9.8% Higher - Tale of the Tape +13.20%
May-29-15 03:29PM  2 Small Biotechs This Pro Is Watching
May-28-15 08:29PM  5 Things Galena Biopharma Wants You to Know at Investopedia
04:10PM  Galena Biopharma to Present at the Sachs Immuno-Oncology BD&L and Investment Forum GlobeNewswire
12:25PM  Galena Could See Lucrative Partnerships at Barrons.com
08:18AM  Can the Rally in Galena Biopharma (GALE) Shares Continue? - Tale of the Tape
May-27-15 01:42PM  Galena Biopharma rises on cancer therapy study +11.97%
07:05AM  Galena Biopharma Announces Publication of Two Abstracts at the 2015 American Society of Clinical Oncology Annual Meeting GlobeNewswire
May-26-15 02:07PM  3 Biotech Stocks Under $10 to Trade for Breakouts at TheStreet
May-22-15 07:05AM  Galena Biopharma to Present GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial Data at the European Hematology Association 20th Congress GlobeNewswire
May-08-15 08:47PM  Galena Biopharma Earnings: NeuVax or Bust at Investopedia
May-07-15 05:00PM  Galena Biopharma Inc Earnings Call scheduled for 5:00 pm ET today
04:20PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex
04:15PM  Galena Biopharma Reports First Quarter 2015 Financial Results GlobeNewswire
Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs across cancer care. Its commercial products include Abstral, a sublingual tablet that is used for the management of breakthrough pain in patients with cancer; and Zuplenz, an oral soluble film for use in the prevention of chemotherapy-induced, radiotherapy-induced, and post-operative nausea and vomiting. The company's lead product candidate, NeuVax (nelipepimut-S), is in Phase III clinical trials for the prevention of recurrence in early- stage and node-positive breast cancer with low to intermediate human epidermal growth factor receptor (HER2) expression; Phase IIb clinical trials in combination with Herceptin for HER2 1+/2+ node-positive and high-risk node-negative breast cancer treatment; and Phase II clinical trials in combination with Herceptin for neoadjuvantly treated node positive and negative HER2 IHC 3+ patients not achieving a pathological complete response. It also develops GALE-301 (folate binding protein), which is in Phase IIa clinical trials for the prevention of recurrence in patients with ovarian and endometrial cancers; and GALE-401 (anagrelide controlled release), which is in a Phase 2 clinical trial for the treatment of patients with myeloproliferative neoplasms to lower elevated platelet levels. Galena Biopharma, Inc. has strategic development and commercialization partnership with Dr. Reddy's Laboratories Ltd. for NeuVax in breast and gastric cancers in India and with Teva Pharmaceuticals in Israel. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Galena Biopharma, Inc. in September 2011. Galena Biopharma, Inc. was founded in 2003 and is based in Portland, Oregon.